Syngene Seals Decade-Long Research Pact With Bristol Myers Squibb Till 2035

OTHER
Whalesbook Logo
AuthorAarav Shah|Published at:
Syngene Seals Decade-Long Research Pact With Bristol Myers Squibb Till 2035
Overview

Syngene International announced an extension of its long-term strategic research collaboration with Bristol Myers Squibb, now set to run until 2035. This deepens a partnership spanning over 25 years and expands the scope of integrated services across the entire drug development lifecycle, including discovery, development, manufacturing, and clinical trials. The agreement aims to accelerate the progression of drug candidates from research to commercialization.

Strategic Extension Deepens Collaboration

The extended collaboration will broaden the scope of integrated services across the drug development lifecycle. This includes significant expansion into discovery and translational sciences, alongside pharmaceutical development, manufacturing, clinical trials, and data and IT services. The primary objective is to enable a seamless progression of potential drug candidates from early research phases directly through to commercialization, a critical step in bringing new medicines to market.

BBRC Centre Strengthened

Syngene's dedicated R&D facility, the Biocon Bristol Myers Squibb Research and Development Center (BBRC) in Bengaluru, established in 1998, has evolved into a major strategic hub. It currently houses approximately 700 Syngene scientists who operate as an extension of Bristol Myers Squibb's global research organization. These teams contribute across therapeutic areas like cardiovascular, fibrosis, immunology, and oncology, playing a key role in accelerating novel compound progression from early discovery to first-in-human studies. This has helped reduce development timelines and costs for Bristol Myers Squibb.

Analyst Optimism on Syngene Stock

Adding to the positive outlook, brokerage firm Macquarie reiterated its "outperform" rating on Syngene earlier this month. The firm set a price target of ₹835 per share, signaling a potential upside of nearly 28% from its previous closing price. Macquarie views Syngene as offering an attractive risk-reward profile, anticipating fundamental improvements alongside sustained valuation appeal. Despite this, shares were trading marginally down at ₹627 by midday on January 19, though still above intraday lows.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.